C E M Griffiths1, S-J Jo2, L Naldi3, R Romiti4, E Guevara-Sangines5, T Howe6, G Pietri7, I Gilloteau8, C Richardson8, H Tian9, M Augustin10. 1. Dermatology Centre, Salford Royal Hospital, NIHR Manchester Biomedical Research Centre, University of Manchester, Manchester, U.K. 2. Department of Dermatology, Seoul National University Hospital, Seoul, Korea. 3. Department of Dermatology, AULSS 8, Ospedale san Bortolo, Vicenza, Italy. 4. Department of Dermatology, Hospital das Clínicas, University of São Paulo (USP), Brazil. 5. Hospital Regional "Lic. Adolfo López Mateos" ISSSTE, México City, Mexico. 6. GfK, London, U.K. 7. Data Pyxis Ltd., St Albans, U.K. 8. Novartis Pharma AG, Basel, Switzerland. 9. Novartis Pharmaceuticals Corporation, East Hanover, NJ, U.S.A. 10. Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany.
Abstract
BACKGROUND: Psoriasis is a chronic, immune-mediated disease, characterized by symptoms that include itching and skin pain and is often associated with comorbidities. Patients have a substantial detriment to quality of life (QoL) and work productivity with associated cost burden. OBJECTIVES: To investigate the incremental burden of comorbidities, itch and affected body areas among systemic eligible patients with psoriasis, using a multinational survey of dermatologists and their patients with psoriasis. METHODS: Multinational data from the Growth from Knowledge (GfK) Disease Atlas Global Real-World Evidence program were used. Eligible patients were identified as those who were currently having or had ever had moderate-to-severe psoriasis, and must have been receiving prescription treatments at the time of the survey. Multivariable regression analyses were conducted to assess the incremental burden among psoriasis patients with physical and psychological comorbidities, itch and affected visible and sensitive body areas vs. psoriasis patients without these conditions, respectively. RESULTS: The study enrolled 3821 patients with psoriasis, from nine countries, with an average Psoriasis Area and Severity Index score of 6·4. The presence of comorbidities was associated with a significant increase in the likelihood of skin pain, lower QoL, greater work impairment and increased usage of medical resources (except in psoriasis patients with obesity and type 2 diabetes). Psoriasis patients suffering from itch and those with visible and sensitive affected body areas also had impaired QoL vs. those without these conditions. CONCLUSIONS: Psoriasis patients with physical and psychological comorbidities, itch and affected visible and sensitive body areas had lower QoL and greater work impairment compared to those without these conditions.
BACKGROUND:Psoriasis is a chronic, immune-mediated disease, characterized by symptoms that include itching and skin pain and is often associated with comorbidities. Patients have a substantial detriment to quality of life (QoL) and work productivity with associated cost burden. OBJECTIVES: To investigate the incremental burden of comorbidities, itch and affected body areas among systemic eligible patients with psoriasis, using a multinational survey of dermatologists and their patients with psoriasis. METHODS: Multinational data from the Growth from Knowledge (GfK) Disease Atlas Global Real-World Evidence program were used. Eligible patients were identified as those who were currently having or had ever had moderate-to-severe psoriasis, and must have been receiving prescription treatments at the time of the survey. Multivariable regression analyses were conducted to assess the incremental burden among psoriasispatients with physical and psychological comorbidities, itch and affected visible and sensitive body areas vs. psoriasispatients without these conditions, respectively. RESULTS: The study enrolled 3821 patients with psoriasis, from nine countries, with an average Psoriasis Area and Severity Index score of 6·4. The presence of comorbidities was associated with a significant increase in the likelihood of skin pain, lower QoL, greater work impairment and increased usage of medical resources (except in psoriasispatients with obesity and type 2 diabetes). Psoriasispatients suffering from itch and those with visible and sensitive affected body areas also had impaired QoL vs. those without these conditions. CONCLUSIONS:Psoriasispatients with physical and psychological comorbidities, itch and affected visible and sensitive body areas had lower QoL and greater work impairment compared to those without these conditions.
Authors: Simon Francis Thomsen; Lone Skov; Lars Erik Kristensen; Morten Størling Hedegaard; Jakob Kjellberg; Tanja Schjødt Jørgensen; Søren Brenøe; Rikke Dodge Journal: Arch Public Health Date: 2020-10-12
Authors: Martin Steinhoff; Alfred F Ammoury; Haytham Mohamed Ahmed; Mohamed Fathy Soliman Gamal; Mahira H El Sayed Journal: Psoriasis (Auckl) Date: 2020-08-20
Authors: Ki Young Huh; Yewon Choi; Jim Nissel; Maria Palmisano; Xiaomin Wang; Liangang Liu; Francisco Ramirez-Valle; Howard Lee Journal: Clin Transl Sci Date: 2021-05-01 Impact factor: 4.689